Table 1.
Demographic and Clinical Characteristics of the Patients
| SBCE sessions, n | 196 |
| SBCE sessions (males/females), n | 131/65 |
| Patients (males/females), n | 108 (69/39) |
| Age, years | 37.6 ± 15.3 |
| Disease duration, months | 105 ± 100 |
| Hemoglobin (g/dL) | 13.2 ± 2.0 |
| Platelet count (104/μL) | 26.3 ± 9.6 |
| Albumin (mg/dL) | 4.1 ± 0.6 |
| C-reactive protein (mg/dL) | 0.74 ± 1.5 |
| CDAI | 107 ± 85 |
| Classification of Montreal | |
| A1 | 37 (18.9) |
| A2 | 122 (62.2) |
| A3 | 37 (18.9) |
| L1 | 65 (33.2) |
| L2 | 0 (0) |
| L3 | 131 (66.8) |
| B1 | 95 (48.5) |
| B2 | 63 (32.1) |
| B3 | 38 (19.4) |
| Perianal disease | 50 (25.5) |
| Past intestinal surgery | 85 (43.4) |
| Smoking | 26 (13.3) |
| Medications | |
| 5ASA | 162 (82.7) |
| Steroid | 26 (13.3) |
| Azathioprine | 36 (18.4) |
| Elemental diet (300–600 kcal/day) | 101 (51.5) |
| Anti-TNFα (infliximab/adalimumab) | 92/27 (60.7) |
| LS | 501 ± 1177 [0–5701] |
| CECDAI | 5.8 ± 5.4 [0–25] |
| SB2/SB3 | 75/121 |
Data are mean ± SD or number (%) [range] of patients